The Board of Directors and the Chief Executive Officer of ODI Pharma AB (“ODI”) hereby publish the annual report of the fiscal year 2019/2020. The annual report, along with the accompanying auditor’s report, is available as an attached file and on the websites of ODI (www.odipharma.com) and Spotlight Stock Market (www.spotlightstockmarket.com). An English translation of the annual report is also available on www.odipharma.com.
For more information on ODI Pharma, please contact:
Derek Simmross, CEO, ODI Pharma AB
E-mail: info@odipharma.com
ODI Pharma AB
ODI Pharma, based on its European network, subsidiaries and affiliates, is a producer and representative of finished pharmaceutical cannabis products with a focus on distribution to the medical cannabis market in Europe through its subsidiary ODI Pharma Polska Sp. z o.o. ODI Pharma intends to provide a high-quality product at a competitive price compared to competitors in Poland, thereby becoming the number one provider of medical cannabis in Poland. ODI Pharma also strives to be on the forefront of understanding the medical applications of the product as well as introducing new, innovative products to the European patients in need. ODI will continue to team up with the most knowledgeable and best renown partners in the industry to achieve its goals.
